LivaNova receives FDA approval for SenTiva device, VNS Therapy System

LivaNova (LIVN) announced it received U.S. Food and Drug Administration approvals for its latest Vagus Nerve Stimulation Therapy System, which consists of the SenTiva implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistant epilepsy.

SenTiva is the smallest and lightest responsive therapy for epilepsy.

The new VNS Therapy Programming System features a wireless wand and new user interface on a small tablet.

Together, the components offer patients with drug-resistant epilepsy a physician-directed customizable therapy with smart technology and proven results to reduce the number of seizures, lessen the duration of seizures and enable a faster recovery.

SenTiva is the first epilepsy device of its size to include detect-and-respond mode, designed to prevent seizures before they start and automatically deliver extra therapy to stop them if they do.

SenTiva also collects and logs events commonly associated with seizures, including a patient’s body position and heart rate variations.

LIVN closed at $74.24.

STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.